Pfizer Inc (PFE)

$28.32 -0.23 (-0.81%)
Market Cap 161.04B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 8.84
Forward PE 9.60
Profit Margin 12.42%
Debt to Equity Ratio 0.75
Volume 30,920,600
Avg Vol 44,932,004
Day's Range N/A - N/A
Shares Out 5.69B
Stochastic %K 82%
Beta 0.43
Analysts Sell
Price Target $28.98

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
Lowkeyoptions
Lowkeyoptions Apr. 4 at 10:03 PM
$NVDS $TSLA $PFE IMAGINE A CEO OF A PHARMA COMPANY GETTING TWO DRUGS TO MARKET THROUGH CLINICAL TRIALS AND NEVER DOING A SINGLE REVERSE SPLIT. $OMER CEO IS THAT GUY!! SURGEON WENT TO STANDFORD AND DUKE MOST CAN'T GIT INTO ONE. PAGES OF BIO MEDICAL PATENT PAGES!! https://patents.justia.com/inventor/thomas-dudler
0 · Reply
NasdaqPulse
NasdaqPulse Apr. 4 at 8:31 AM
$LLY $PFE $NVO already moved. $REGN now scrambling. 👉Click to view @NasdaqPulse for timely updates amid the volatility. This “100% pharma tariff” headline? Not what it seems. It’s a leverage play. The message from D.C. is simple: Accept MFN-style pricing + bring production back to the U.S. = avoid the hit Stay global + protect margins = face the pressure So far, big pharma isn’t fighting… they’re signing. Meanwhile, biosimilars + generics are getting a pass (for now), which tells you exactly where the target is: high-margin branded drugs with overseas exposure. This isn’t about fixing supply chains overnight — it’s about forcing pricing alignment and reshaping pharma economics.
0 · Reply
UsingAGodAlgorithm
UsingAGodAlgorithm Apr. 4 at 3:32 AM
$SE (-75% from short entry) We are the best on ST as far as we have seen. Check our profile. We also covered these names . $DE $ARM $PFE $NVO
0 · Reply
sam92
sam92 Apr. 4 at 1:48 AM
$PFE https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/how-pfizers-lyme-vaccine-trial-results-could-shape-pipeline/amp
0 · Reply
DragonAlgo
DragonAlgo Apr. 3 at 10:05 PM
🐉 $PFE CALL — DragonAlgo® Signal Contract: PFE CALL Expiry: 2026-04-10 | Strike: $28.50 | Type: CALL Option Plan (premium): Entry: $0.31 Stop: $0.22 TP1: $0.40 TP2: $0.53 TP3: $0.74 🔗 https://dragonalgo.com
0 · Reply
DrSilbergleit
DrSilbergleit Apr. 3 at 8:03 PM
$SPY $QQQ $XLE $USO $PFE “We are watching a superpower developing super scientific capabilities, and our whole effort is how to slow [China] down, rather than how to become better than them,” says Albert Bourla, chairman and CEO of Pfizer, Inc. “The only way to be able not to lose the edge that we have—it is if we do changes inside our American ecosystem of biotech, of science, of academia, of pharmaceuticals, of capital markets, venture capital.”
0 · Reply
PickAlpha
PickAlpha Apr. 3 at 3:38 PM
PickAlpha Morning Report - Macro Events: 2026.04.03 Event Analysis - 1/4: Trump orders new pharmaceutical tariffs and resets metals-derivative duties, creating immediate pricing and supply-chain implications for pharma, metals, industrials and power-grid equipment | View: Policy shock alters competitive dynamics for pharmaceuticals and metals… $PFE $REGN $SLX $CPER
0 · Reply
topstockalerts
topstockalerts Apr. 3 at 3:04 PM
Trump Tariffs: One-Year Impact A year after Trump’s tariffs, U.S. companies are adjusting supply chains and absorbing costs amid changing policies (reciprocal tariffs struck down; global 10–15% tariffs; Section 232 on steel/aluminum). Retail: Large chains managed; smaller firms struggled. Price increases passed to consumers in some cases. Examples: Walmart, Home Depot, Abercrombie & Fitch, American Eagle, Gap, Dollar Tree. Automotive: Billions in tariffs absorbed; supply chains shifted and U.S. production increased. Examples: GM, Ford, Stellantis, Toyota, Nissan, Honda. CPG: Costs rose for imported materials; mitigated via pricing, sourcing changes, or absorbed. Examples: Procter & Gamble, McCormick, Constellation Brands, J.M. Smucker. Pharma: Price agreements and tariffs incentivized domestic manufacturing. Examples: Pfizer, Eli Lilly, Merck, Gilead, Bristol Myers, Novo Nordisk, GSK, Novartis, AbbVie, Johnson & Johnson. $WMT $HD $GM $PFE $LLY
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 3 at 2:49 PM
$OMER again show me another pre clinical to fda approved never had a reverse split. Just got 240 million upfront cash follow up up to 2.1 billion. Ceo is a legend Double surgeon orthopedic stanford and duke pages of medical patent. Dude is overqualified for life. Alien 👽 👾 https://patents.justia.com/inventor/thomas-dudler $RGC $PFE $RHHBY
1 · Reply
CapitalSignalWorks
CapitalSignalWorks Apr. 3 at 2:34 PM
Big shift happening in pharma M&A right now… The race for T-cell engager therapies is heating up fast. These next-gen bispecific antibodies are redefining cancer treatment—and big players aren’t sitting on the sidelines. $AMGN and $PFE are активно moving in, snapping up innovative biotech platforms to lock in leadership in this high-growth space. The message is clear: whoever controls T-cell engager tech could dominate the future of oncology. This isn’t just a trend—it’s a strategic land grab in one of the most promising areas of modern medicine. Watch the deal flow… because the next acquisition could be a game-changer.
0 · Reply
Latest News on PFE
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (April 2026)

Apr 4, 2026, 8:10 AM EDT - 10 hours ago

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (April 2026)

ADP AEG APH ARCC ARE BX CAG

Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs

Apr 2, 2026, 11:14 AM EDT - 2 days ago

Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs

NVO LLY

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

Apr 1, 2026, 11:39 AM EDT - 3 days ago

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

BNTX

Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines

Apr 1, 2026, 10:13 AM EDT - 3 days ago

Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines

Pharma Offers Defensive Plays in an Uncertain Market. Charts Say Buy These 2 Stocks.

Mar 30, 2026, 10:44 AM EDT - 5 days ago

Pharma Offers Defensive Plays in an Uncertain Market. Charts Say Buy These 2 Stocks.

GSK LLY NVO PPH

Pfizer: Why Wall Street Habitually Overestimates Target Price

Mar 27, 2026, 3:48 PM EDT - 8 days ago

Pfizer: Why Wall Street Habitually Overestimates Target Price

Why Pfizer Remains A Strong Buy In 2026

Mar 27, 2026, 10:46 AM EDT - 8 days ago

Why Pfizer Remains A Strong Buy In 2026

Pfizer: Undervalued High-Yield Giant With A Pipeline Built For The Next Decade

Mar 25, 2026, 9:15 AM EDT - 10 days ago

Pfizer: Undervalued High-Yield Giant With A Pipeline Built For The Next Decade

Pfizer: Time To Buy The Turnaround

Mar 25, 2026, 2:06 AM EDT - 10 days ago

Pfizer: Time To Buy The Turnaround

Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts

Mar 24, 2026, 10:00 AM EDT - 11 days ago

Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts

An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive

Mar 23, 2026, 12:46 PM EDT - 12 days ago

An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusive

VALN

Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive

Mar 23, 2026, 10:35 AM EDT - 12 days ago

Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive

VALN

Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

Mar 23, 2026, 9:36 AM EDT - 12 days ago

Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

VALN

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

Mar 23, 2026, 7:07 AM EDT - 12 days ago

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

VALN

Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial

Mar 23, 2026, 7:02 AM EDT - 12 days ago

Pfizer, Valneva Report Strong Efficacy Data From Lyme Vaccine Trial

VALN

Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

Mar 23, 2026, 6:47 AM EDT - 12 days ago

Pfizer-Valneva Lyme disease shot shows more than 70% efficacy in late-stage trial

VALN

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

Mar 23, 2026, 6:45 AM EDT - 12 days ago

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

VALN

5 ‘Healthy' Dividends Paying Up To 14.1%

Mar 22, 2026, 9:45 AM EDT - 13 days ago

5 ‘Healthy' Dividends Paying Up To 14.1%

ARE BME DOC HQH

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

Mar 20, 2026, 4:30 PM EDT - 15 days ago

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

Mar 19, 2026, 6:45 AM EDT - 16 days ago

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

TrumpRx lists many medicines at prices higher than paid in UK

Mar 18, 2026, 2:23 PM EDT - 17 days ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK JNJ

Pfizer: I'm Still Expecting A Massive Rebound

Mar 18, 2026, 9:00 AM EDT - 17 days ago

Pfizer: I'm Still Expecting A Massive Rebound

Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial

Mar 17, 2026, 7:49 AM EDT - 18 days ago

Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Mar 17, 2026, 6:45 AM EDT - 18 days ago

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

Expect Pfizer To Comeback: Take The Dividend While Waiting For Capital Appreciation

Mar 13, 2026, 5:01 PM EDT - 22 days ago

Expect Pfizer To Comeback: Take The Dividend While Waiting For Capital Appreciation

Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study

Mar 9, 2026, 7:27 AM EDT - 26 days ago

Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study

Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

Mar 9, 2026, 6:45 AM EDT - 26 days ago

Pfizer's Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (March 2026)

Mar 7, 2026, 8:15 AM EST - 4 weeks ago

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (March 2026)

ADP ARCC BX CAG GLPI MPLX MSFT

Wall Street Breakfast Podcast: India To Buy Russian Oil As War Disrupts Supplies

Mar 6, 2026, 6:05 AM EST - 4 weeks ago

Wall Street Breakfast Podcast: India To Buy Russian Oil As War Disrupts Supplies

AMD GOOG GOOGL LLY NVDA NVO

China approves Pfizer GLP-1 drug for weight management

Mar 6, 2026, 12:40 AM EST - 4 weeks ago

China approves Pfizer GLP-1 drug for weight management

Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund

Mar 5, 2026, 4:48 PM EST - 4 weeks ago

Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund

Seven S&P500 Ideal 'Safer' March Dividend Dogs

Mar 4, 2026, 11:31 AM EST - 4 weeks ago

Seven S&P500 Ideal 'Safer' March Dividend Dogs

AMCR ARE BBY BEN BXP CAG CCI

Pfizer's Portfolio Renewal In Progress - High Yields For The Patient

Mar 4, 2026, 9:09 AM EST - 4 weeks ago

Pfizer's Portfolio Renewal In Progress - High Yields For The Patient

NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

Mar 4, 2026, 8:55 AM EST - 4 weeks ago

NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

SMWB

Pfizer's Quiet Cash Comeback

Mar 3, 2026, 9:50 AM EST - 4 weeks ago

Pfizer's Quiet Cash Comeback

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

Mar 3, 2026, 8:10 AM EST - 4 weeks ago

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

PRGO XRAY

Pfizer Inc. (PFE) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 2, 2026, 1:27 PM EST - 4 weeks ago

Pfizer Inc. (PFE) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Pfizer CEO flags issues with FDA's vaccine leadership

Mar 2, 2026, 11:14 AM EST - 4 weeks ago

Pfizer CEO flags issues with FDA's vaccine leadership

The High Dividend Yield Bull Market: 3 Compelling 6% Yields

Mar 2, 2026, 4:51 AM EST - 4 weeks ago

The High Dividend Yield Bull Market: 3 Compelling 6% Yields

ABBV AMGN AVGO BTI DIV ENB GTY

14 Ideal 'Safer' Dividend Buys From 29 Of 69 March Graham Value All-Stars (GVAS)

Mar 1, 2026, 8:10 AM EST - 4 weeks ago

14 Ideal 'Safer' Dividend Buys From 29 Of 69 March Graham Value All-Stars (GVAS)

ARCC BBVA E EQNR ETD FINV GSL

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

Feb 27, 2026, 10:00 AM EST - 5 weeks ago

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

5 'Safer' Dividend Buys In Barron's 23 Better February Bets Than T-Bills

Feb 26, 2026, 7:48 AM EST - 5 weeks ago

5 'Safer' Dividend Buys In Barron's 23 Better February Bets Than T-Bills

BBY CAG EQR FRT KEY KMI LYB

U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Feb 24, 2026, 2:29 PM EST - 5 weeks ago

U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

Feb 24, 2026, 7:45 AM EST - 5 weeks ago

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

Pfizer in diabetes drug deal with Sciwind Biosciences

Feb 23, 2026, 10:26 PM EST - 5 weeks ago

Pfizer in diabetes drug deal with Sciwind Biosciences

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

Feb 23, 2026, 3:15 PM EST - 5 weeks ago

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

MRK MRNA

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Feb 23, 2026, 10:00 AM EST - 5 weeks ago

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer: A Risky 6.3% Yield For Income-Oriented Investors

Feb 20, 2026, 11:47 PM EST - 6 weeks ago

Pfizer: A Risky 6.3% Yield For Income-Oriented Investors

Is There 25% Downside For Pfizer Stock?

Feb 18, 2026, 12:00 PM EST - 6 weeks ago

Is There 25% Downside For Pfizer Stock?

Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game

Feb 18, 2026, 11:30 AM EST - 6 weeks ago

Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game

Lowkeyoptions
Lowkeyoptions Apr. 4 at 10:03 PM
$NVDS $TSLA $PFE IMAGINE A CEO OF A PHARMA COMPANY GETTING TWO DRUGS TO MARKET THROUGH CLINICAL TRIALS AND NEVER DOING A SINGLE REVERSE SPLIT. $OMER CEO IS THAT GUY!! SURGEON WENT TO STANDFORD AND DUKE MOST CAN'T GIT INTO ONE. PAGES OF BIO MEDICAL PATENT PAGES!! https://patents.justia.com/inventor/thomas-dudler
0 · Reply
NasdaqPulse
NasdaqPulse Apr. 4 at 8:31 AM
$LLY $PFE $NVO already moved. $REGN now scrambling. 👉Click to view @NasdaqPulse for timely updates amid the volatility. This “100% pharma tariff” headline? Not what it seems. It’s a leverage play. The message from D.C. is simple: Accept MFN-style pricing + bring production back to the U.S. = avoid the hit Stay global + protect margins = face the pressure So far, big pharma isn’t fighting… they’re signing. Meanwhile, biosimilars + generics are getting a pass (for now), which tells you exactly where the target is: high-margin branded drugs with overseas exposure. This isn’t about fixing supply chains overnight — it’s about forcing pricing alignment and reshaping pharma economics.
0 · Reply
UsingAGodAlgorithm
UsingAGodAlgorithm Apr. 4 at 3:32 AM
$SE (-75% from short entry) We are the best on ST as far as we have seen. Check our profile. We also covered these names . $DE $ARM $PFE $NVO
0 · Reply
sam92
sam92 Apr. 4 at 1:48 AM
$PFE https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/how-pfizers-lyme-vaccine-trial-results-could-shape-pipeline/amp
0 · Reply
DragonAlgo
DragonAlgo Apr. 3 at 10:05 PM
🐉 $PFE CALL — DragonAlgo® Signal Contract: PFE CALL Expiry: 2026-04-10 | Strike: $28.50 | Type: CALL Option Plan (premium): Entry: $0.31 Stop: $0.22 TP1: $0.40 TP2: $0.53 TP3: $0.74 🔗 https://dragonalgo.com
0 · Reply
DrSilbergleit
DrSilbergleit Apr. 3 at 8:03 PM
$SPY $QQQ $XLE $USO $PFE “We are watching a superpower developing super scientific capabilities, and our whole effort is how to slow [China] down, rather than how to become better than them,” says Albert Bourla, chairman and CEO of Pfizer, Inc. “The only way to be able not to lose the edge that we have—it is if we do changes inside our American ecosystem of biotech, of science, of academia, of pharmaceuticals, of capital markets, venture capital.”
0 · Reply
PickAlpha
PickAlpha Apr. 3 at 3:38 PM
PickAlpha Morning Report - Macro Events: 2026.04.03 Event Analysis - 1/4: Trump orders new pharmaceutical tariffs and resets metals-derivative duties, creating immediate pricing and supply-chain implications for pharma, metals, industrials and power-grid equipment | View: Policy shock alters competitive dynamics for pharmaceuticals and metals… $PFE $REGN $SLX $CPER
0 · Reply
topstockalerts
topstockalerts Apr. 3 at 3:04 PM
Trump Tariffs: One-Year Impact A year after Trump’s tariffs, U.S. companies are adjusting supply chains and absorbing costs amid changing policies (reciprocal tariffs struck down; global 10–15% tariffs; Section 232 on steel/aluminum). Retail: Large chains managed; smaller firms struggled. Price increases passed to consumers in some cases. Examples: Walmart, Home Depot, Abercrombie & Fitch, American Eagle, Gap, Dollar Tree. Automotive: Billions in tariffs absorbed; supply chains shifted and U.S. production increased. Examples: GM, Ford, Stellantis, Toyota, Nissan, Honda. CPG: Costs rose for imported materials; mitigated via pricing, sourcing changes, or absorbed. Examples: Procter & Gamble, McCormick, Constellation Brands, J.M. Smucker. Pharma: Price agreements and tariffs incentivized domestic manufacturing. Examples: Pfizer, Eli Lilly, Merck, Gilead, Bristol Myers, Novo Nordisk, GSK, Novartis, AbbVie, Johnson & Johnson. $WMT $HD $GM $PFE $LLY
0 · Reply
Lowkeyoptions
Lowkeyoptions Apr. 3 at 2:49 PM
$OMER again show me another pre clinical to fda approved never had a reverse split. Just got 240 million upfront cash follow up up to 2.1 billion. Ceo is a legend Double surgeon orthopedic stanford and duke pages of medical patent. Dude is overqualified for life. Alien 👽 👾 https://patents.justia.com/inventor/thomas-dudler $RGC $PFE $RHHBY
1 · Reply
CapitalSignalWorks
CapitalSignalWorks Apr. 3 at 2:34 PM
Big shift happening in pharma M&A right now… The race for T-cell engager therapies is heating up fast. These next-gen bispecific antibodies are redefining cancer treatment—and big players aren’t sitting on the sidelines. $AMGN and $PFE are активно moving in, snapping up innovative biotech platforms to lock in leadership in this high-growth space. The message is clear: whoever controls T-cell engager tech could dominate the future of oncology. This isn’t just a trend—it’s a strategic land grab in one of the most promising areas of modern medicine. Watch the deal flow… because the next acquisition could be a game-changer.
0 · Reply
CapitalismUSA
CapitalismUSA Apr. 3 at 12:35 PM
$PFE Pfizer investors…I hope you are aware of the multi billion patent infringement lawsuit that will be going against you! If you don’t believe me, just ask Moderna.
0 · Reply
EthelBurkhardt272
EthelBurkhardt272 Apr. 3 at 12:08 PM
$JNJ $UNH $PFE defensive names quietly holding up. not sexy, but money parks here when things get shaky
1 · Reply
WunDumFuc
WunDumFuc Apr. 3 at 11:47 AM
$SPY $QQQ $NIFTY50.NSE $PFE $SUNPHARMA.NSE
0 · Reply
ericmarcellus
ericmarcellus Apr. 3 at 11:28 AM
A 100% tariff on patented drugs would be a major shock to the pharma cost structure Big names under pressure: • $PFE ($28.24, -0.95%) • $MRK ($120.22, +0.01%) → Potential margin compression as costs rise and pricing flexibility tightens Potential beneficiaries: • Generics like $TEVA could capture share as buyers look for cheaper alternatives Broader market impact: • Healthcare ETF $XLV ($146.71, -0.62%) may see increased volatility as the sector reprices risk • Could accelerate a shift in manufacturing toward lower-cost regions • Might even force a new wave of biotech innovation to offset cost pressures This isn’t just a headline — it’s a structural change that could reshape pharma economics if it sticks.
0 · Reply
kristianwx90
kristianwx90 Apr. 3 at 9:26 AM
$PFE flat with pressure
0 · Reply
DragonAlgo
DragonAlgo Apr. 3 at 7:12 AM
🐉 $PFE CALL — DragonAlgo® Signal Contract: PFE CALL Expiry: 2026-04-10 | Strike: $28.50 | Type: CALL Option Plan (premium): Entry: $0.31 Stop: $0.22 TP1: $0.40 TP2: $0.53 TP3: $0.74 🔗 https://dragonalgo.com
0 · Reply
MorganHoratio
MorganHoratio Apr. 3 at 7:07 AM
The spouse of Susan Collins just picked up corporate bonds from Pfizer ($PFE). Here’s why that matters Bond buyers care about stability, cash flow, and downside protection — not hype. This kind of move suggests: Confidence in Pfizer’s ability to service debt Lower perceived default risk Preference for income + safety over equity upside Translation: this isn’t a “moonshot” signal… it’s a defensive confidence play. In a market full of uncertainty, smart money sometimes whispers instead of shouts. Worth watching how $PFE equity reacts from here.
1 · Reply
BigBreakingWire
BigBreakingWire Apr. 3 at 5:00 AM
US to impose up to 100% tariffs on patented pharma and APIs from July 31, 2026; 20% for onshoring firms rising to 100% by 2030. 53% drugs imported, only 15% APIs domestic; generics exempt. Read 👇 https://bigbreakingwire.in/us-imposes-100-tariffs-on-pharma-imports/ $SPY $QQQ $NIFTY50.NSE $PFE $SUNPHARMA.NSE
0 · Reply
MarcoRossi
MarcoRossi Apr. 3 at 12:58 AM
$PFE Manufacture: Made in USA USA. As an American company with 175 years of history, we are proud to be world leaders in medical innovation. Our supply, manufacturing and distribution facilities in the US. U.S. focus on ensuring that all Pfizer products are made to the highest standards of quality, safety and effectiveness
0 · Reply
Judykay
Judykay Apr. 2 at 8:38 PM
$PFE Come join us $KODK
0 · Reply
markbrogan
markbrogan Apr. 2 at 8:15 PM
$PFE Pfizer is an American company. Why are people posting about tariffs for Pfizer?
1 · Reply
Typecheck
Typecheck Apr. 2 at 8:08 PM
$PFE Darn. Looks like it hit a wall.
0 · Reply